ATE424417T1 - Diagnose und behandlung von hepatischen krankheiten - Google Patents

Diagnose und behandlung von hepatischen krankheiten

Info

Publication number
ATE424417T1
ATE424417T1 AT99922996T AT99922996T ATE424417T1 AT E424417 T1 ATE424417 T1 AT E424417T1 AT 99922996 T AT99922996 T AT 99922996T AT 99922996 T AT99922996 T AT 99922996T AT E424417 T1 ATE424417 T1 AT E424417T1
Authority
AT
Austria
Prior art keywords
disorders
madcam
disorder
compositions
useful
Prior art date
Application number
AT99922996T
Other languages
English (en)
Inventor
Sherman Fong
Kenneth Hillan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE424417T1 publication Critical patent/ATE424417T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99922996T 1998-05-13 1999-05-12 Diagnose und behandlung von hepatischen krankheiten ATE424417T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7840598A 1998-05-13 1998-05-13

Publications (1)

Publication Number Publication Date
ATE424417T1 true ATE424417T1 (de) 2009-03-15

Family

ID=22143829

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99922996T ATE424417T1 (de) 1998-05-13 1999-05-12 Diagnose und behandlung von hepatischen krankheiten

Country Status (10)

Country Link
EP (1) EP1078006B1 (de)
JP (2) JP4817494B2 (de)
AT (1) ATE424417T1 (de)
AU (1) AU3986699A (de)
CA (1) CA2330000C (de)
DE (1) DE69940503D1 (de)
DK (1) DK1078006T3 (de)
ES (1) ES2321994T3 (de)
IL (2) IL139129A0 (de)
WO (1) WO1999058573A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1308726B1 (de) * 2001-11-05 2006-03-08 Warner-Lambert Company LLC Screeningverfahren für Modulatoren von Integrinen
US20070202097A1 (en) * 2003-03-10 2007-08-30 Krissansen Geoffrey W Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof
MX370489B (es) * 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
EP1904531B1 (de) * 2005-07-08 2010-10-06 Pfizer Limited Madcam-antikörper
EP3326645B1 (de) * 2010-10-25 2020-03-18 Biogen MA Inc. Verfahren zur bestimmung von unterschieden in einer alpha-4-integrin-aktivität durch korrelation von unterschieden in svcam- und/oder smadcam-ebenen
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
JP6970975B2 (ja) * 2016-07-20 2021-11-24 国立大学法人京都大学 ＩｇＧ４関連疾患の検査方法
EP3652211A1 (de) 2017-07-14 2020-05-20 Pfizer Inc. Antikörper gegen madcam
WO2019113280A1 (en) * 2017-12-06 2019-06-13 Emory University Methods of managing hepatic steatosis
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024673A1 (en) * 1995-02-10 1996-08-15 Leukosite, Inc. Mucosal vascular addressins and uses thereof
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor

Also Published As

Publication number Publication date
CA2330000C (en) 2015-06-23
DK1078006T3 (da) 2009-06-02
CA2330000A1 (en) 1999-11-18
ES2321994T3 (es) 2009-06-15
AU3986699A (en) 1999-11-29
DE69940503D1 (de) 2009-04-16
JP2010280659A (ja) 2010-12-16
EP1078006A1 (de) 2001-02-28
JP2002514660A (ja) 2002-05-21
JP4817494B2 (ja) 2011-11-16
IL139129A (en) 2006-09-05
IL139129A0 (en) 2001-11-25
EP1078006B1 (de) 2009-03-04
WO1999058573A1 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
Postma et al. Long term effects of vincristine on the peripheral nervous system
BR0011000A (pt) Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico
DE69940503D1 (de) Diagnose und behandlung von hepatischen krankheiten
DE69833971D1 (de) Verfahren zur behandlung von alzheimerschen krankheit
BRPI0712322A2 (pt) compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
TR200002784T2 (tr) Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar
ATE548354T1 (de) Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
NO993393D0 (no) Fotokjemoterapeutiske blandinger
BRPI0413326A (pt) métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel
EA200000848A1 (ru) Способ селективного снижения числа или активности макрофагов (варианты), способ лечения или профилактики заболевания субъекта (варианты), способ диагностики заболевания у субъекта
Sewal et al. Increase in seizure susceptibility in sepsis like condition explained by spiking cytokines and altered adhesion molecules level with impaired blood brain barrier integrity in experimental model of rats treated with lipopolysaccharides
BRPI0413745A (pt) horário mde dosagem para agentes anticancerìgenos erbb2
Costanza et al. Therapy of malignant melanoma with an imidazole carboxamide and bis‐chloroethyl nitrosourea
ATE497763T1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
Attarian et al. Magnetic stimulation using a triple‐stimulation technique in patients with multifocal neuropathy without conduction block
Claus et al. Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam
WO2004064869A3 (en) Amyloid-binding, metal-chelating agents
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
BRPI0416591A (pt) métodos e reagentes para o tratamento de distúrbios inflamatórios
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
Stanton et al. Diphenylhydantoin protects against hypoxia-induced impairment of hippocampal synaptic transmission
MA27690A1 (fr) Composition pharmaceutique androgene et procede pour le traitement de la depression.
Piecoro et al. Seizures in patients receiving concomitant antimuscarinics and acetylcholinesterase inhibitor
EP1363528A4 (de) Verfahren zur diagnose und behandlung von herzerkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties